Market Definition 

Tissue Dissociation is used to isolate cells from tissues. Tissue dissociation enzymes are reagents that affect the yield and quality of human pancreatic islets required for islet transplantation. Tissue dissociation and cell harvesting are principal applications for enzymes in tissue culture research and cell biology studies. 

Global tissue dissociation market is estimated to reach $XX million by 2027, growing at a CAGR of 11.2% till 2027. 

Market Dynamics 

The rising prevalence and number of cancer cases is expected to drive the market growth. For instance, according to the American Institute for Cancer Research, breast cancer is the second most common cancer globally. According to the World Health Organization (WHO), In 2020, the new cancer has risen to 19.3 million and 10.0 million deaths globally. According to the World Health Organization (WHO), globally, lung cancer accounts for 2.09 million cases in 2018. According to the American Cancer Society, in 2020, an estimate of 228,820 new cases of lung cancer was diagnosed in the United States. According to the World Health Organization (WHO), every year, around 900,000 people worldwide are diagnosed with blood cancer. Globally, around 2 million new cases of breast cancer are diagnosed in 2018. According to the World Health Organization (WHO), globally, colorectal cancer accounts for 1.80 million cases in 2018. According to the American Cancer Society's (ACS), in 2020, an estimate of 147,950 adults in the United States are expected to diagnose with colorectal cancer. According to the American Cancer Society, it is estimated that in 2020 there will be 191,930 new cases of prostate cancer and 33,330 deaths from prostate cancer in the United States. The tissue dissociation process is used for tumor analysis. The analysis of tumor-resident cell and stem cell populations requires proper methods for tissue dissociation and cell purification. Companies and research institute has established methods for the enzymatic and mechanical dissociation of solid tumors and optimized them according to the specific needs of a given tissue or cell type. Further, increasing research activities for tissue dissociation is a key driving factor of the market. However, risk associated with tissue dissociation might hamper the market growth. Moreover, developing products and technology related to tissue dissociation would provide lucrative opportunities for the market in coming years. 

Market Segmentation 

The global tissue dissociation market is mainly classified based on type and application. Type is further segmented into Epithelial Tissue and Connective Tissue. By application, the market is divided into Research Institutes, Pharmaceutical Companies, Biotechnology Companies, and Diagnostic Laboratories. 

Based on application, Biotechnology Companies was dominating the tissue dissociation market in 2020, owing to the increasing research activities associated with tissue dissociation. Biopharmaceutical companies are focusing on R&D in various therapeutic areas to introduce new drugs in the market. For instance, BioIVT, a leading provider of research models and services for drug development, has introduced dissociated tumor cell (DTC) product line to its immunology portfolio. DTCs are patient-derived primary tumor cells isolated from fresh tumor tissue using mechanical and enzymatic dissociation. Researchers use patient derived DTCs to determine how specific cohorts of cancer cells react to different drug therapies. DTCs provide the closest representation of the clinical scenario. DTCs also help to advance personalized medicine.  

Regional Analysis 

Based on geography, the global tissue dissociation market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided in the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa. 

North America was dominating the tissue dissociation market in 2020 due to the rising prevalence and number of cancer cases. For instance, in 2020, around 1.8 million new cancer cases were diagnosed and 606,520 cancer deaths in the United States. Moreover, developing products and technology related to tissue dissociation is driving the market growth in North American regions. For instance, S2 Genomics, a manufacturer of automated tissue sample preparation systems, has introduced the Singulator 100 System. The Singulator 100 System automates the processing of solid tissue samples into suspensions of single cells or nuclei with high yields and from small samples for a wide range of single-cell biology and genomic analyses. Automated tissue preparation workflows can help ensure high-quality single-cell data and accelerate single-cell research for genomics, cell biology, and other applications. The Singulator 100 automates and standardizes the dissociation process of solid tissues, helps for researchers to reproducibly prepare suspensions of high-quality, highly viable cells or nuclei with minimal variability. 

Competitive landscape 

Key players operating in the tissue dissociation industry include Miltenyi Biotec, Worthington Biochemical, F. Hoffmann-La Roche, Becton Dickinson, Thermo Fisher Scientific, VitaCyte, Merck KGaA, and StemCell. 

Commercialization of new tissue dissociation kit, partnership between companies to provide tissue dissociation kits, increasing research activities associated with tissue dissociation, and the rising funds by the companies and government bodies for cancer research are some of the strategies adopted by the major companies. For instance, on June 15, 2020, Bit Bio, a Cambridge-based synthetic biology company, has raised $41.5 million funding to decode “cellular identity” to generate every cell type of the human body. The company’s platform technology, opti-ox, enables precise reprogramming of stem cells and induces them to take on a new identity and become specialized cells, such as those in the liver, brain, or immune system. The investment is also used for the development of new cancer-defeating cell therapies obstructed by the scarcity of human cells. 

Tissue Dissociation Market Key Segments: 

By Type 

• Epithelial Tissue 
• Connective Tissue 

By Application 

• Research Institutes 
• Pharmaceutical Companies 
• Biotechnology Companies 
• Diagnostic Laboratories 

Industry Players 

• Miltenyi Biotec 
• Worthington Biochemical 
• F. Hoffmann-La Roche 
• Becton Dickinson 

• Thermo Fisher Scientific 
• VitaCyte 
• Merck KGaA 
• StemCell 

What Report Provides 

• Full in-depth analysis of the parent Industry 
• Important changes in market and its dynamics 
• Segmentation details of the market 
• Former, on-going, and projected market analysis in terms of volume and value 
• Assessment of niche industry developments 

• Market share analysis 
• Key strategies of major players 
• Emerging segments and regional growth potential